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Abstract: Adipose tissue is an abundant source of stem cells. However, liposuction cannot yield cell
quantities sufficient for direct applications in regenerative medicine. Therefore, the development of
GMP-compliant ex vivo expansion protocols is required to ensure the production of a “cell drug”
that is safe, reproducible, and cost-effective. Thus, we developed our own basal defined xeno- and
serum-free cell culture medium (UrSuppe), specifically formulated to grow human adipose stem
cells (hASCs). With this medium, we can directly culture the stromal vascular fraction (SVF) cells in
defined cell culture conditions to obtain hASCs. Cells proliferate while remaining undifferentiated, as
shown by Flow Cytometry (FACS), Quantitative Reverse Transcription PCR (RT-qPCR) assays, and
their secretion products. Using the UrSuppe cell culture medium, maximum cell densities between
0.51 and 0.80 × 105 cells/cm2 (=2.55–4.00 × 105 cells/mL) were obtained. As the expansion of
hASCs represents only the first step in a cell therapeutic protocol or further basic research studies,
we formulated two chemically defined media to differentiate the expanded hASCs in white or
beige/brown adipocytes. These new media could help translate research projects into the clinical
application of hASCs and study ex vivo the biology in healthy and dysfunctional states of adipocytes
and their precursors. Following the cell culture system developers’ practice and obvious reasons
related to the formulas’ patentability, the defined media’s composition will not be disclosed in
this study.
Keywords: UrSuppe; defined cell culture; xeno- and serum-free cell culture; adipogenic differentiated
adipose-derived stromal cells; white and beige/brown adipocyte; platelet lysate
1. Introduction
Adipose tissue is usually classified by morphology into white, brown, or beige sub-
sets [1,2]. The primary white adipose tissue (WAT) depot is further subdivided as either
subcutaneous (SAT) or visceral (VAT). On the other hand, the minor white adipose de-
pots include the dermal WAT (dWAT) and bone marrow adipose tissue (MAT), which are
considered distinct from SAT and VAT [3]. Rodents are commonly used to study human
metabolism and obesity. However, it is unclear to what extent rodent fat pads are a suitable
human adipogenesis model in health and disease. Indeed, there are essential anatomical
differences that should be considered [4,5]. One distinction between human and rodent
VAT is that humans have a clear detectable omental WAT (oWAT), whereas rodents have a
large perigonadal WAT (pgWAT). Additionally, mouse SAT is separated from dermal adi-
pose tissue by a smooth muscle layer, whereas in humans, the SAT is continuously found
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with dermal adipose tissue. Finally, rodent adipose tissue deposition is strikingly dissimilar
from humans, as is the fat pad composition and location associated with sex hormones [4].
A striking difference between the two species also exists regarding brown adipose tissue
(BAT) regulation mechanisms or WAT “browning” [6,7]. Besides the macroscopic anatomi-
cal or morphological discrepancies, human and mouse WAT’s cellular compositions also
show essential dissimilarities. One of the most striking examples of this is the marked
differences in steady-state immune cell composition between human and mouse WAT [8].
This observation suggests that the two species’ adipose tissue’s critical immunoregulatory
processes might be considerably different. Moreover, numerous examples at the molecular
level highlight the differences between human and murine adipose tissue. For example,
one of them concerns the mechanism through which glucocorticoids (GCs) affect adipoge-
nesis. Indeed, GCs increase LMO3 (a proadipogenic factor) in human adipose stem cells
(ASCs), but not in mouse primary ASCs [9]. Furthermore, in vitro cortisol treatment in-
creases UCP1 expression in human brown adipocytes while suppressing it in mouse brown
adipocytes [7]. Another example concerns the Wnt1-inducible signaling pathway protein-1
(WISP1); in humans, its expression increases during adipocyte differentiation and has a
positive effect on adipogenesis, whereas in mice, it inhibits adipocyte differentiation [10,11].
Finally, estrogen sulfotransferase inhibits adipocyte differentiation in mice, but promotes
adipogenesis in humans [12,13]. In contrast, Mesoderm-specific transcript (MEST) acts
as an inhibitor of human adipogenesis, but stimulates murine adipogenesis [14]. Thus,
the results obtained from rodent models or murine cell lines require validation in human
cell culture models to demonstrate their relevance to human physiology. At this point,
one might wonder if it is ultimately convenient to work with mouse models as the results
cannot always be used to understand the complex biology of the human adipose tissue.
This line of reasoning can also be extended to other organs or tissues. Therefore, it is
not surprising that the pharmaceutical industry has realized how dangerous it is to rely
solely on animal models during the early stages of the drug discovery pipeline [15,16].
Indeed, preclinical studies based on transformed animal cell lines, conventional cell culture
conditions with undefined serum-containing media, and animal models have usually
proven unable to predict drug efficacy in human trials [17,18]. The same problems concern
basic research; murine cell lines, extensively used over many years and until now, are
not a good study model for finding remedies for the worldwide obesity pandemic and
obesity-related diseases. It is essential to improve the in vitro studies by introducing
primary human adipose tissue-derived cells with defined cell culture media, which offer a
more relevant and versatile adipocyte biology model than murine cell lines cultured with
undefined media [19].
With these concerns in mind, we developed our own basal defined serum- and xeno-
free cell culture medium (UrSuppe), specifically formulated to grow primary human adipose
stem cells (hASCs). Here, we show that we can put the stromal vascular fraction (SVF)
cells extracted from human donors’ adipose tissue directly in culture with our chemically
defined medium to obtain hASCs. Remarkably, this is also the case for cryopreserved cell
samples (SVF or serum-free passaged hASCs). In both of these cases, the cells proliferate
while preserving their undifferentiated status. We also determined the basic growth-
dependent parameters of the hASCs grown in our defined medium as well as investigated
on which substrate the cells grow best. As the expansion of hASCs represents only the first
step in a cell therapeutic protocol or for further basic research studies, we developed two
chemically defined media to differentiate the expanded hASCs in white or beige/brown
adipocytes. These new chemically defined media could help translate research projects
into the clinical application of hASCs or establish superior models to study the biology of
human adipocytes and their precursors ex vivo. More realistically, studies with primary
hASCs will contribute to an improved understanding of adipocyte biology in healthy and
dysfunctional states [20,21] or their role in developing or their role in developing severe
diseases, such as certain types of tumors [22,23].
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2. Materials and Methods
The detailed description of the chemicals and reagents used in this study is shown in
the online Supplementary Information Table S1.
2.1. Isolation and Cultivation Protocols
2.1.1. Extraction of Adipo-Cutaneous Tissue
Human adipose tissue samples were obtained from tissue excess originating from
surgical interventions performed in the Department of Plastic, Reconstructive and Aesthetic
Surgery at the Ospedale Regionale di Lugano (Switzerland). All patients who donated
their spare adipo-cutaneous tissue provided written agreement in compliance with the
directives of the local Ethics Committee of the Canton of Ticino, which approved the
project and its procedures (project reference number: CE 2915). Briefly, the cellular source
used in this study originated from adipo-cutaneous tissue harvested from the abdominal
region of female patients undergoing autologous breast reconstruction under general
anesthesia. Initially, a symmetrical diamond-shaped abdominal flap depending on the
deep inferior epigastric artery and its perforating vessels (DIEP-flap) was removed between
the umbilicus and the pubis. After that, any excess of adipo-cutaneous tissue that was not
used for breast reconstruction was packed into two sterile bags to avoid contamination
and was handed over to allow for further tissue proceeding. Adipose tissue biopsies were
kept at room temperature and processed within 24 h [24] to obtain the stromal vascular
fraction (SVF).
2.1.2. Isolation of Stromal Vascular Fraction (SVF)
Extraction of the SVF from human adipose tissue, in vitro expansion of ASCs, and
their cryopreservation were in line with the ethical principles outlined in the Declaration
of Helsinki and in compliance with the directives of the Ethics Committee of the Canton
of Ticino (Switzerland). Briefly, adipose tissue was washed with DPBS with Ca2+ and
Mg2+ (Bioconcept, Allschwil, Switzerland) in a Gosselin sterile container (Corning, New
York, USA), cut into smaller pieces, and homogenized with an immersion blender. The
fat was dissociated by digestion with collagenase type B, animal origin free (Worthington,
Biochemical Corp., Lakewood, NJ), at a final concentration of 0.28 Wünsch U/mL for 45 min
at 37 ◦C under constant, but gentle agitation [24]. The dissociated cells were subsequently
filtered through a 100 µm and then through a 40 µm sieve cell strainer (Becton Dickinson,
Franklin Lakes, NJ). All centrifugation steps were completed at 600× g for 10 min at room
temperature. At the end of the extraction procedure, the cellular pellet was resuspended in
PBS without Ca2+ and Mg2+ (Biowest, Nuaillè, Frace) with 1% injectable human albumin
(CLS Behring, Bern, Switzerland) or in the cell culture medium. More complete and detailed
information can be found online in the Supplementary Information (S1: Isolation of the
stromal vascular fraction from human adipose tissue, Figures S1–S3).
2.1.3. Cell Seeding and Culture
Cells were always and exclusively cultivated using our proprietary defined serum- and
xeno-free cell culture medium, “UrSuppe”. The medium contains only defined molecules,
some recombinant human growth factors, and injectable human albumin in the µg range.
After the characterization and enumeration of the SVF cells through flow cytometry, the
cells were seeded at a density of approximately 30,000 ASCs/cm2 in Fibronectin coated
vessels (Corning, New York, USA) and kept in a humidified incubator at 37 ◦C and 5% CO2.
This initial passage of the primary cell culture was referred to as passage 0 (P0). Details
can be found in the Supplementary Information (S2: Characterization of the cells of the
SVF from adipose tissue, S3: Initial plating of cells of the SVF for expansion, and Figure S4).
Cells were maintained in culture until they achieved 75–90% confluence. They were then
either collected and cryopreserved or replated in new Fibronectin coated tissue culture
vessels at a density of 5000–10,000 ASCs/cm2. The medium was changed every 2–3 days,
always keeping 20–50% of the conditioned medium, until the cells reached confluency
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between 75 and 90%. Cells were detached with TrypLEe Select (Life Technologies, Thermo
Fisher Scientific, Waltham, USA) for 2 min at 37 ◦C, then washed with PBS supplemented
with 1% injectable human albumin and pelleted by centrifugation at 400× g for 5 min.
After discarding the supernatant, the cells were counted with Trypan Blue (Thermo Fisher
Scientific, Waltham, USA), resuspended in UrSuppe, and passaged or used for various
tests. Please see the Supplementary Information (S4: Basic guidelines for working with
serum-free (SF) media and Figure S5) for further details and explanations.
2.2. Serum-Free Cryopreservation of the Cells (SVF & hASCs)
After isolation of the SVF or after detaching the expanded hASCs, the cells were
resuspended in 1 mL of pre-cooled (4–8◦C) freezing solution Synth-a-Freeze CTS (Thermo
Fisher Scientific, Waltham, USA) at a concentration of at least 1 to 5 × 106 cells/mL (or 0.5
to 2 × 106 cells/mL for expanded hASCs). The cellular suspension was then transferred
in a 2 mL plastic screw-capped cryotube (Nunc, Thermo Fisher Scientific, Waltham, USA)
chilled on ice. Finally, the cryotubes were moved into the Mr. Frosty Cryo 1 ◦C Freezing
Container (Nalgene, Thermo Fisher Scientific, Waltham, MA, USA) and put in a −80 ◦C
freezer. The next day, the cryopreserved cells were transferred to a liquid nitrogen tank
for final storage. In some cases, to enhance cell viability, and thus to obtain a higher yield
upon thawing, the cryovials were frozen using a freezing device (NalgeneTM Cryo 1 ◦C
Freezing Container, Thermo Fisher Scientific, Waltham, MA, USA) or a controlled cooling
rate protocol. The thawing protocol consists of a dilution system. The cryopreserved cell
samples were quickly thawed by dilution with UrSuppe medium to have a final maximal
DMSO (Dimethyl Sulfoxide) concentration of 1% or less. The cells were seeded without
washing or centrifuging. After 5–6 h, when the cells adhered, the cell culture medium
was replaced with a fresh cell culture medium. More information is reported in the
Supplementary Information (S5: Cryopreservation and thawing of the SVF and Figure S6).
2.3. Influence of Surface Coating on hASCs Attachment and Growth
hASCs at passage P2 were seeded at a low density (~ 2′000 cells/cm2) in the screenMa-
trix 96-well plate (denovoMatrix, Dresden, Germany) and in 96-well plates without coating
(TPP Techno Plastic Products AG, Trasadingen, Switzerland) as a negative control with
the UrSuppe medium. After one week of culture, a cell proliferation assay was performed
using the Cell Counting Kit 8 (Dojindo Laboraties Inc., Kumamoto, Japan) according to the
manufacturer’s instruction. After the incubation with the substrate WST-8, the amount of
the formazan dye generated by the activity of the cells, which is directly proportional to
the number of living hASCs, was measured at 450 nm using a microplate reader (Anthos
Reader 2001, Anthos Mikrosysteme GmbH, Krefeld, Germany). The average absorbance of
the control wells (blank) was subtracted from that of the test wells with cells. All the data
were then expressed as relative absorbance using the negative control cells as a reference
value. The clean values obtained in this way were depicted in scatter plots showing the
means and the standard deviations.
2.4. hASC Growth Characterization under Planar, Static Conditions
Two-dimensional (2D) growth characterization of previously isolated hASCs (see
Table 1) was performed as duplicates (n = 2 per donor) in pre-coated T25-flasks (10 µg/cm2
r-fibronectin; Sigma Aldrich, St. Louis, MO, USA) with UrSuppe cell culture medium
(5 mL). For this purpose, the cryopreserved, patient-derived hASCs (P0) were thawed
and pre-cultured in pre-coated T75-flasks (10,000 hASCs/cm2, 37 ◦C, 5% CO2, 80% rH)
in order to achieve the required cell numbers to inoculate 44 × T25-flasks per donor
(10,000 hASCs/cm2, see Table 1). The hASC growth characteristics were assessed over ten
days by harvesting two T25-flasks per donor and experiment (2 mL TrypLE Select at 37 ◦C,
2 min) every day. The cell density, substrate, and metabolite measurements (Glc, Lac, Amn)
were carried out using a NucleoCounter NC-200 (Chemometec, Allerod, Denmark) and
a Cedex Bio (Roche Diagnostics, Rotkreuz, Switzerland), respectively. Cell growth and
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substrate/metabolite concentrations were modeled using an unstructured growth model
recently published by our groups [25,26]. Microscopic pictures (EVOS M7000, Thermo
Fisher Scientific, Waltham, MA, USA) were taken daily to evaluate the cell morphology
and the cell confluency. In each case, partial medium exchanges of 40% and 60% were
performed for each donor on days 4 and 8. To measure the metabolite concentration after
the medium exchange, 1 mL of supernatant from one T-flask was removed and substituted
with 1 mL of UrSuppe cell culture medium. This additionally treated T-flask was used for
the next day’s sampling. Detailed formulas used to calculate growth parameters can be
found in Supplementary Materials Section S6.
Table 1. Overview of donor-related data. The passage number and population doubling level (PDL) refer to the cell
inoculum used for the growth characterization.
Donor Gender Age Region Health Stats Pinoculated PDLinoculated
D-I Female 46 Abdomen Healthy P2 6.3
D-II Female 26 Abdomen Post-chemotherapy P2 6.5
D-III Female 50 Abdomen Post-chemotherapy P2 6.0
D-IV Female 50 Abdomen Healthy P3 8.1
2.5. Characterization of Expanded Human ASCs
2.5.1. Flow Cytometry Analysis
A small aliquot of freshly extracted cells of the SVF was first counted and then diluted
to a concentration of ~7.5 × 106 cells/mL in FACS buffer: PBS supplemented with 1%
injectable human albumin and 50 ng/µL of human immunoglobulins (CLS Behring, Bern,
Switzerland) 40 µL (~300,000 cells) were stained with CD34-BV650 (Brilliant Violet 650),
CD45-PC7, CD73-FITC (BioLegend, San Diego, CA), CD146-PE, CD36-APC (Miltenyi
BioTech, Bergisch, Germany), 7-amino-actinomycin D (7-AAD) (Becton Dickinson, Franklin
Lakes, NJ), and Syto 40 Blue Fluorescent Nucleic Acid Stain (Life Technologies, Thermo
Fisher Scientific, Waltham, MA, USA). After 20 min of incubation, erythrocytes were lysed
with 200 µL of VersaLyse solution (Beckman Coulter Inc., Pasadena, CA, USA).
Expanded and induced cells, 100 µL of the cell suspension (~50,000 cells) was pipetted
into a well, and gently mixed with the appropriated antibodies combination. Each test
contained a different mixture of the following antibodies: CD26-FITC, CD73-FITC, CD90-
APC, CD95-FITC, CD105-PE, CD142-APC (BioLegend, San Diego, CA, USA), CD34-FITC,
CD36-FITC, CD137-APC, CD146-PE (Miltenyi BioTech, Bergisch, Germany), CD55-BV421,
CD248-BV421, 7-AAD (Becton Dickinson, Franklin Lakes, NJ, USA), CD54-PE, CD140a-
APC, and CD106-PC7 (Thermo Fisher Scientific, Waltham, MA, USA). Cells were incubated
for 20 min at room temperature in the dark. Finally, the sample was diluted with 100 µL
FACS buffer before the acquisition of the data.
All antibodies were titrated to optimize the signal-to-noise ratio and used at a con-
centration of 50 ng/test. Isotype controls and specific mAbs were used at the same final
concentrations. Further information about the antibodies used for this analysis can be
found in the Supplementary Information Table S2. Stained cells were analyzed using the
Cytoflex flow cytometer (Beckman Coulter Inc., Pasadena, CA, USA) and, subsequently,
the raw data were processed with the Kaluza software (Beckman Coulter Inc., Pasadena,
CA, USA). Fluorescence compensation was assessed using single stained control particles
(VersaComp Antibody Capture Bead Kit, Beckman Coulter Inc., Pasadena, CA, USA) or
cells to determine the labeled antibodies’ spill-over coefficients for the stainings.
2.5.2. Quantitative Reverse Transcription PCR (RT-qPCR) Analysis
Total RNAs were purified using the Nucleospin®RNA kit (Macherey-Nagel, Düren,
Germany) according to the manufacturer’s instructions. The kit’s purification procedure
also includes an on-column digestion step with DNase I. RNA purity and quantity were
assessed with the NanoDrop device (Thermo Fisher Scientific, Waltham, USA) and to-
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tal RNA integrity was periodically verified by conventional agarose gel electrophoresis.
cDNA was obtained from 400 ng RNA using the GoScriptTM Reverse Transcription System
(Promega, Madison, WI). The protocol can be found in the Supplementary Information
(Table S3). RT-qPCR of the following genes PREF1, SOX9, ZFP521, WISP2, NOTCH1, DLL1,
PPARG, ZFP423, RUNX2, CD146, WISP1, DKK1, CD34, CD36, α-KLOTHO, β-KLOTHO,
CD26, CD55, CD142, CD248, FABP4, ADIPONECTIN, LEPTIN, UCP1, and PGC1α was per-
formed using the SsoAdvancedTMUniversal SYBR®Green Supermix kit (Biorad, Hercules,
CA) and detected with the CFX Connect system (Biorad, Hercules, CA, USA). RT-qPCR
was performed using 20 ng of cDNA for each gene, and ACTB was used as an internal
control. Each primer pair product was checked for proper amplification by agarose gel
electrophoresis. We exclusively used primers, which gave rise to single sharp bands of
the expected size. Primer sequences, temperature, and cycle conditions can be found in
Supplementary Information (Tables S4 and S5). Data were analyzed with the CFX software
to calculate the relative fold gene expression using the formula 2−∆∆Ct.
2.6. hASCs’ Differentiation
2.6.1. Adipogenic Differentiation—WAT and BAT
Two completely chemically defined serum- and xeno-free differentiation media were
developed, UrSuppe-WAT: to induce hASCs in white adipose tissue (US-WAT); and UrSuppe-
BAT: to induce hASCs in beige/brown adipose tissue (US-BAT). Both contain specific
recombinant human growth factors to induce the maturation in white or beige adipocytes,
dexamethasone, and injectable albumin in the µg range. For adipogenic differentiation,
hASCs were seeded at P2 with UrSuppe medium in collagen I coated 60 mm Petri dishes
(Greiner Bio-One, Kremsmünster, Austria). After reaching full confluency, the cells were
cultured in an adipogenic differentiation medium (US-WAT or US-BAT). The medium was
changed every four days up to a total incubation period of ten days for WAT and seven
days for BAT.
2.6.2. Oil Red O Evaluation
Oil Red O (Sigma-Aldrich Inc., St. Louis, MO) staining was performed to examine
cytoplasmic lipid vesicles during adipogenesis. Briefly, the Oil Red O stock solution (3%
[w/v] in isopropanol, Sigma-Aldrich Inc., St. Louis, MO) was diluted 3:2 with deionized
water, and filtrated to prepare the Oil Red O working solution. The samples were washed
with PBS, fixed with a fixing solution (2% formaldehyde, 0.2% glutaraldehyde in PBS,
Sigma-Aldrich Inc., St. Louis, MO, USA) for 15 min, washed with deionized water, and
stained for 5 min with Oil Red O working solution. Residual dye was washed out with
deionized water and samples were directly observed by light microscopy. Cells were
incubated in the dark for 15 min with a solution of 10 µg/mL Hoechst (Molecular Probes,
Eugene, OR, USA) diluted in PBS. The vessels were then washed with PBS, and nuclei
were counted using an automated Lionheart FX system (BioTek Instruments Inc., Winooski,
VT, USA).
To evaluate the induction efficiency, plates were incubated with 100% isopropanol for
5 min, with gentle rocking, to extract the Oil Red O dye. The liquid phase was then trans-
ferred to spectrophotometer cuvettes, and the absorbance was read at 518 nm (Specord40,
Analytic Jena, Germany), using 100% isopropanol as a control to subtract the background
signal. Evaluation of the adipogenic differentiation is based on quantifying the Oil Red O
absorbance, normalized for the number of cells present in the cell culture vessel.
2.6.3. JC-10 Staining and Fluorescence Microscopy
The JC-10 assay provides a robust assay method for monitoring mitochondria mem-
brane potential (MPP) changes. This molecule is analog to JC-1 with improved solubility
in aqueous media and increased sensitivity to detect subtler changes in matrix metallo-
proteases (MMP). Beige and brown adipocytes are characterized by the fact that they can
depolarize the mitochondrial membrane potential, leading to the dissipation of chemical
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energy into heat. In normal cells, JC-10 accumulates in mitochondria, selectively generating
an orange J-aggregate emission profile (590 nm). However, upon maturation into a beige
or brown adipocyte, as the membrane potential decreases, JC-10 monomers are generated,
resulting in a shift to green emission (525 nm). Thus, this is a very convenient method of
recording the switch from undifferentiated ASCs into brown/beige adipocytes. Experi-
mentally, the test was carried out as follows. After induction of the hASCs with US-WAT
or US-BAT medium, the cells were washed twice with PBS and then incubated in a basal
medium containing JC-10 (Adipogen, San Diego, CA, USA. Stock solution 1000× in DMSO:
10 mM), and diluted according to the manufacturer’s instructions (Final concentration: 10
µM), for 30 min at 37 ◦C. After this step, the cells were washed with PBS to remove an
excess of reagent. Then, samples were directly observed under an inverted fluorescence
microscope (UV laser 405 nm) Nikon Eclipse Ti (Nikon, Minato, Tokyo, Japan).
2.6.4. Characterization of Human Differentiated ASCs: RT-qPCR Analysis
At the end of the induction or culture period, the medium was removed, and the
cells were washed with PBS. Then, 1.5 mL of extraction buffer (7M Urea, 1% SDS, 0.35 M
NaCl, all chemicals from Sigma-Aldrich Inc., St. Louis, MO) was added to the cell culture
vessel, and the lysate was collected with the help of a cell spatula (TPP, Trasadingen,
Switzerland). As quickly as possible, the lysate was transferred into a 5 mL ED Eppendorf
tube (Eppendorf, Hamburg, Germany) containing 1.5 mL of phenol/chloroform/isoamyl
alcohol 25:24:1 solution (all chemicals from Sigma-Aldrich Inc., St. Louis, MO, USA) and
mixed vigorously. The aqueous phase was then transferred to a new ED tube containing
3.5 mL of 100% EtOH (Sigma-Aldrich, St. Louis, MO, USA), mixed, and centrifuged at
2200× g for 10 min at room temperature (RT). The supernatant was discarded, and the
pellet was first washed with 100% EtOH and then resuspended in 100 µL of Accugene
water (Lonza, Basel, Switzerland). Finally, the pellet was processed as indicated in the
RT-qPCR analysis section (Section 2.5.2).
2.6.5. Secretome Profiler
The conditioned cell culture medium (UrSuppe, US-WAT, and US-BAT) was analyzed
to detect secreted cell factors. Each conditioned medium was filtered through a 0.22 µm
syringe mesh (Jet Biofil, Guangzhou, China) to remove cellular debris, then 1 mL of each
supernatant was incubated overnight with a nitrocellulose membrane containing many
different capture antibodies. The array procedure was carried out according to the instruc-
tions provided with the Proteome Profiler Human Adipokine Array Kit (R&D Systems,
Minneapolis, MN, USA). The secondary biotinylated detection antibodies were highlighted
by the use of Streptavidin conjugated IRDye 800 CW (Li-Cor Corporate, Lincoln, NE,
USA). Positive signals were detected after scanning the membrane using an Odyssey®CLX
Imaging System (Li-Cor Corporate, Lincoln, NE, USA). Data were analyzed using Li-Cor
software to evaluate the signal intensity ratio between the different adipokine spots and
the positive reference spot.
2.7. Statistical Analysis
Statistical analysis was performed using SPSS or Graph Pad Prism software. The
differences between groups were evaluated with a one-way analysis of variance (ANOVA)
and Bonferroni post-hoc test. The assumption of the analysis was checked: normal dis-
tribution and homogeneity of the variance. p-values lower than 0.05 were considered as
statistically significant.
3. Results
3.1. Comprehensive Phenotypic Characterization of Freshly Extracted Cells of the SVF
To culture SVF cells immediately after extraction in the defined serum-free conditions,
it is crucial to know the type and the relative number of cells present in the preparation
to seed them at the optimal density. If the appropriate density is not hit, it is unlikely to
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obtain a confluent hASC P0 culture. Therefore, based on the existing literature [27–29], we
designed a new combination of cell surface markers and intracellular stains to characterized
freshly extracted SVF cells. This analysis is made more difficult by the presence of a
large amount of debris in a cell suspension. As shown in Figure 1A, the use of Syto
40 Blue Fluorescent Nucleic Acid Stain (stains all nucleated cells), of 7-AAD (live/dead
discrimination), and the gating for small size cells, helped us to define the nucleated living
target cells. Subsequently, we use an anti-CD45-PC7 antibody to differentiate stromal
from blood cells (Figure 1A4). Finally, the CD45 negative stromal cells were analyzed for
the expression of CD34 and CD146, leading to the biparametric plot B1 shown in Figure
1B. This allowed for the determination of four different populations: (1) CD34+, CD45−,
CD146−: ASCs; (2) CD34+, CD45−, CD146+: Endothelial cells; (3) CD34−, CD45−, CD146+:
Mural cells; (4) CD34−, CD45−, CD146−: Other not defined cells. With the five-color flow
cytometry assay, we were able to count the hASCs present in the sample. We could use this
information to seed the cells at an optimal density, making it almost certain that the hASCs
would take root in the defined serum-free conditions.
CD34 and CD146 are highly informative markers because they are expressed starting
from early progenitors to more differentiated and mature adipocytes [30–35]. However,
unfortunately, they are also present on the surface of several different types of adult
vascular wall resident progenitor or mature cells [36–38], giving rise to diverse populations
of cells with varying degrees of stemness or maturation. Therefore, it is judicious to add
two additional colors to the basal panel to deepen the analysis and better characterize the
cells of the SVF. Thus, the results obtained with three tests using three different seven-
colors panels are shown in Figure 1B. Each subpopulation of plot B1, obtained with the
first five colors, can be further analyzed with the addition of two additional antibodies.
The rationale for choosing these three combinations is as follows:
• CD26-FITC/CD36-APC, “cell fate” panel. Recently, the CD26 marker was found
on the surface of early adipocyte progenitor cells. In contrast, the CD36 surface
marker is directly involved in adipocyte differentiation, and its expression level
increases gradually when ASCs are induced to mature into adipocytes [30,33,39–41].
Therefore, these two markers allow for the discrimination of early progenitors from
more differentiated cells.
• CD73-FITC/CD36-APC, “ASCs characterization” panel. CD73 belongs to the canoni-
cal “MSCs” markers, and recently, it has been demonstrated that it can mark multi-
potent stromal cells [42]. This markers combination is beneficial for identifying early
progenitors, and in combination with CD36, it is possible to exclude more differen-
tiated and mature cells and to obtain a more precise count of the ASCs present in
the SVF.
• CD31-FITC/CD144-APC, “endothelial cells” panel. CD31(PECAM-1) is a classical
pan-endothelial cells marker expressed constitutively on early and mature vascular
endothelial cells [43]. On the other hand, CD144 (VE-Cadherin) is a strictly endothelial-
specific adhesion molecule located at the junction between endothelial cells. It is
indispensable to the correct organization of the vasculature and for endothelial assem-
bly [44]. As a result, these two antibodies allow for the identification of cells with an
endothelial origin.
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Figure 1. Representative flow cytometry analysis of stromal vascular fraction (SVF) cells based on our seven-color staining
procedure. (A) The gating strategy used to find viable target cells is shown. Syto 40 marks all nucleated cells, and 7-AAD
discriminates between living and dead (plot A1 and A2, respectively). In the next two gates (plot A3 and A4, respectively),
we selected cells that are relatively small and CD45−. (B) Representative analysis of the SVF cells extracted from human
subcutaneous adipose tissue. CD45− target cells were first analyzed for the expression of CD34-BV650 and CD146-PE. This
leads to four sub-populations of cells (plot B1). Except for the lower left quadrant of plot B1, the cells present in the three
other quadrants were further investigated for the expression of three pairs of new markers: (1) CD31-FITC/CD144-APC
(plots B2, B7, & B10). (2) CD26-FITC/CD36-APC (plots B3, B6, B9). (3) CD73-FITC/CD36-APC (plots B4, B5, B8). Data in
A and B are from a representative patient. See the Supplementary Information (S2: Characterization of the cells of the SVF
from adipose tissue and Table S2) for more details about the markers used for this flow cytometry analysis.
Thus, the further analysis of the four sub-populations defined in plot B1 (Figure 1B)
with the three combinations of antibodies described above leads to these observations:
• The CD34+, CD45−, and CD146− cells are negative for endothelial markers (plot
B10) and the majority of them are positive for CD73 and negative for CD36 (plot B8).
Finally, a significant number of these cells are CD26+/CD36− (plot B9). This profile is
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compatible with early progenitor cells, and for this reason, we named the population
of the lower right quadrant of the plot B1 as ASCs.
• The majority of the CD34+, CD45−, and CD146+ cells are positive for the endothelial
markers (plot B7). Some of them are also CD144+, and thus mature endothelial cells.
They also strongly express CD36 and are CD73 negative (plot B5). Interestingly, blot
B6 shows that the majority of these cells are CD26+/CD36+. CD26 has been recently
described as a marker for early precursors [45]. Seeing it co-expressed with CD36 [40],
a typical marker present on mature or differentiating cells, is surprising and worth
highlighting. Taken together, the upper right quadrant of plot B1 mainly contains cells
of endothelial origin at different stages of maturation.
• The majority of the CD34−, CD45−, and CD146+ cells are negative for the tested
markers, except for CD36 (plot B2, B3, and B4), which is highly expressed. We,
therefore, labeled the cells of the upper left quadrant of plot B1 as mural cells.
• The cells of the lower left quadrant (CD34−, CD45−, and CD146−) of plot B1 are not
defined and have not been further analyzed.
In conclusion, we have developed an effective protocol for the flow cytometric analysis
of cells extracted from the human subcutaneous tissue, which allows us to divide the SVF
cells into well-defined sub-populations. Given the growing heterogeneity discovered
between and within the ASC populations, a clear definition of the cell type present in
the sample will become increasingly important. This knowledge is also fundamental for
technical reasons. Indeed, before putting freshly extracted SVF cells in culture under
defined xeno- and serum-free conditions, it is essential to identify and enumerate the
putative hASCs present in the preparation. This information is necessary to seed the SVF
cells at an optimal density, allowing their cultivation from the beginning under defined
conditions without serum or other not defined additives such as the platelet lysate. This
is the most appropriate strategy if one wants to be (almost) sure of obtaining a confluent
culture of hASCs at passage P0.
3.2. Influence of Surface Coating on hASCs’ Attachment and Growth
Fetal Bovine Serum (FBS) contains attachment and spreading factors. Therefore, it
is often not necessary to coat the culture vessels when working with traditional serum-
containing media. On the other hand, working in serum-free conditions requires tissue
culture vessels pre-coated with extracellular matrix (ECM) components. As the interaction
of the cells with the ECM can affect their growth [46], we wanted to determine which
substrate performs best with hASCs cultured in our serum-free cell culture medium. For
this purpose, we used the “screenMatrix” (denovoMatrix GmbH, Dresden, Germany),
which consists of a 96-well plate coated with 24 different biologically relevant peptides non-
covalently linked to four different highly sulphated glycosaminoglycans (GAGs): synthetic
dextran sulfate, heparin, chondroitin, and dermatan [47,48]. hASCs obtained from three
different donors were tested independently and the results are summarized in Figure 2. The
cells’ growth in the 96 wells was monitored using a commercial colorimetric cell viability
assay [49] as described in the Materials and Methods. We first grouped all the absorbance
values measured at 450 nm according to the four types of sulphated GAGs used to form the
different coating matrices (see Figure 2A). As a result, the four GAGs used as an anchoring
matrix for the 24 types of peptides do not significantly influence the capacity to attach and
promote the growth of the ASCs in serum-free conditions. On the other hand, the results
revealed the importance of the peptides to culture these cells successfully. Indeed, among
the 24 types of tested peptides, 14 ultimately failed to sustain the attachment and the growth
of hASCs. Low performing peptides belonged to the laminin family (laminin peptide 1–7,
and laminin peptide 7 + RGD), osteocalcin peptide, E-cadherin peptide, tenascin peptide 1
and 2, TGF peptide, NCAM peptide, and collagen IV peptide (data not shown). Figure 2B
shows the results of the 10 peptides that allow for good adhesion and growth of the cells.
Although the best result was achieved with the bone sialoprotein (BS) peptide followed
by the fibronectin (FN) peptide, we decide to use the latter because several FN coated
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cell culture vessels are already commercially available. Furthermore, it has been reported
that FN, in combination with Pref-1, inhibits adipocyte differentiation [50,51]. Therefore,
FN or FN-derived peptides are very appropriate substrates for growing and expanding
hASCs while maintaining a high degree of stemness. For this reason, we routinely culture
hASCs on Corning PureCoat™ ECM Mimetic Fibronectin Peptide plasticware [52], and all
experiments of this study were performed using cells grown and expanded in serum-free
conditions on this type of vessels.
Figure 2. Identifying attachment substrates necessary for human adipose stem cells’ (hASCs) ad-
herence to cell culture surface, spreading, and growth under serum-free conditions. Human ASCs
obtained from three different donors were used to screen a 96-well plate coated with 24 different
peptides non-covalently linked to four different highly sulphated glycosaminoglycans (GAGs: syn-
thetic dextran sulfate, heparin, chondroitin, and dermatan) [47,48]. The cells’ growth in the 96-well
plate was evaluated using a commercial colorimetric cell viability assay. (A) Values of relative ab-
sorbance measured at 450 nm and classified according to the four types of sulphated GAGs (synthetic
dextran sulfate, heparin, chondroitin, and dermatan) were used as a backbone for the formation
of the different coating matrices. The four GAGs do not have a great influence on cell attachment
and growth. (B) Ten different peptides non-covalently linked to highly sulphated GAGs strongly
influence the ability of hASCs to attach and grow in the test micro-wells. The results obtained with
the 14 poor-performing peptide-combinations are not shown. As in Figure 2A, cell proliferation was
measured using a commercial colorimetric kit. Histograms show the means ± standard deviations of
the measured relative absorbances for hASCs obtained from three different donors. FN = fibronectin;
VN = vitronectin; BS = bone sialoprotein; OP = osteopontin peptide; BMP2 = bone morphogenetic
protein; PP = perlacan peptide; ColI = collagen I peptide; FGF = fibroblast growth factor.
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3.3. hASC Growth under Planar, Static Conditions
Figure 3 shows light microscopic images of patient-derived hASCs during the growth
characterization study in the T25-flasks. It is recognizable that the hASCs attached well
to the fibronectin-coated surface under serum-free conditions. After 4–6 h, nearly all
inoculated cells (viability ≥ 96%) spread out and were mitogenically active. The cells
exhibited a fibroblast-like or fibroblastoid cell morphology, with minimum and maximum
cell diameters in the range of 10 µm to 69 µm and 25 µm to 315 µm (on day 1). Interestingly,
the average cell sizes of the hASCs from the different donors were slightly different. Cell
size analysis of detached cells (hASCs in suspension) showed that hASCs from D-I (18.1 ±
0.2 µm) and D-III (18.2 ± 0.2 µm) were on average 10% smaller than those from D-II (19.5
± 0.3 µm) and D-IV (19.4 ± 0.1 µm). In all cases, cell confluency increased immediately
after the cell attachment phase as a cell number function. Cell confluency of nearly 80%
to 90% was achieved by day 5. After day 5, the increase in cell confluency slowed down
owing to the reduced cell proliferation rate caused by the higher incidence of cell contact
inhibition. Hyperconfluent conditions were achieved in all cases by the end of the cell
growth characterization study (day 10). From a visual perspective, no significant differences
in morphology (i.e., shape, granularity) were found between the four donors during the
culture time under the serum-free conditions.
Figure 3. Light microscopic pictures of patient-derived hASCs during cell growth in T25-flasks. Scale bar = 275 µm. d1 =
after cell attachment, d5 = nearly fully confluent, d10 = hyperconfluent.
Figure 4a–d shows the cell density’s time-dependent profiles and the substrate and
metabolite concentration. It is clear that, in all cases, the hASCs followed a classical
exponential growth curve. The highest cell densities were achieved with 0.76 ± 0.05 × 105
hASCs/cm2 (=3.80 ± 0.25 × 105 hASCs/mL) and 0.80 ± 0.09 × 105 hASCs/cm2 (=4.00 ±
0.45× 105 hASCs/mL) for donor D-I and D-III, respectively. The maximum cell densities of
D-II and D-IV were at 0.51 ± 0.03 × 105 hASCs/cm2 (=2.55 ± 0.15 × 105 hASCs/mL) and
0.68 ± 0.08 × 105 hASCs/cm2 (=3.40 ± 0.40 × 105 hASCs/mL), on average 35% and 13%
lower, respectively. During the culture period, cell viability was, in all cases, always >90%.
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Owing to the cells’ metabolic activity during the growth phase, glucose was consumed,
and lactate and ammonia were produced. In all cases, the glucose concentration did not
drop below 11 mmol/L owing to the medium’s regular partial exchanges. The maximum
lactate and ammonia concentrations were measured to range from 5.83 to 8.44 mmol/L
and 1.13 to 1.76 mmol/L, respectively, in all cultures. According to Higuera et al., 2009 [53];
He et al., 2013 [54]; Chen et al., 2009 [55]; and D. Schop et al., 2009 [56] and 2010 [57], lactate
and ammonia did not, however, reach growth-inhibiting concentrations (Lac = 25–35 mM,
Amn = 2.5 mM). The unstructured growth model well approximated time courses of the
cell densities, the substrate, and metabolite concentrations. Thus, the results highlight the
exponential growth characteristics and the Monod-type growth behavior of the hASCs
under the serum-free conditions in the T25-flask cultures.
Figure 4. Time-dependent profiles of cell densities (left) and substrate/metabolite concentrations (right) in T25-flasks (n = 2
per donor). D-I (a), D-II (b), D-III (c), and D-IV (d). Partial medium exchanges of 40% and 60% were performed on days 4
and 8, respectively. The symbols represent the experimentally measured values collected from offline measurements. The
lines represent the simulated time courses.
Table 2 summarizes the calculated growth-dependent parameters for the different
donors (D-I to D-IV). The achieved maximum cell densities corresponded to the maximum
population doubling level (PDL) and expansion factor (EF) in the range of 2.4 to 3.0
and 5.1 to 8.0, respectively. Interestingly, the specific growth rate was highest for D-I
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(0.45 ± 0.01 d−1) and D-IV (0.38 ± 0.02 d−1). Thus, high growth rates do not necessarily
result in the highest cell densities because of the limited growth area available. Specific
growth rates for D-II and D-III were 0.36 ± 0.02 d−1 and 0.30 ± 0.03 d−1, respectively.
Salzig et al., 2016 [58] reported specific growth rates for human bone marrow-derived
mesenchymal stem cells (hBM-MSCs) cultivated in a serum-free culture medium in the
range of 0.38 to 0.45 d−1 (td = 36.9 to 43.7 h). Comparable specific growth rates of 0.31 to
0.47 d−1 (td = 35.4 to 53.6 h) were also reported by Heathman et al., 2015 [59] and Jossen et al.,
2020 [25]. Specific glucose consumption rates were between 0.30 and 0.74 pmol/cell/d for
the investigated donors and, therefore, in a close range to values reported by Jossen et al.,
2020. Owing to the metabolization of glucose, specific lactate production rates of between
0.43 and 1.19 pmol/cell/d were calculated and resulted in YLac/Glc of between 1.22 and
1.60. According to our expectations, glucose was mainly metabolized into lactate via the
glycolysis pathway. Hence, only little energy was gained by the cells from OXPHOS, which
was in agreement with the literature data (Sart et al., 2014 [60]). The specific ammonia
production was in the range between 0.09 and 0.26 pmol/cell/d.
Table 2. Overview of the main growth-dependent parameters in the 2D cultivations (n = 2 per donor).
No. Xmax PDL * EF ** µ td YLac/Glc qGlc qLac qAmn
(-) (105cells/cm2) (-) (-) (d−1) (h) (mmol/mmol) (pmol/cell/d)
D-I 0.76 ± 0.05 2.9 ± 0.1 7.6 ± 0.7 0.45 ± 0.01 36.7 ± 0.5 1.41 ± 0.16 0.30 ± 0.10 0.43 ± 0.05 0.09 ± 0.04
D-II 0.51 ± 0.03 2.4 ± 0.1 5.1 ± 0.4 0.36 ± 0.02 45.6 ± 2.3 1.47 ± 0.21 0.65 ± 0.08 0.95 ± 0.01 0.16 ± 0.03
D-III 0.80 ± 0.09 3.0 ± 0.2 8.0 ± 1.2 0.30 ± 0.03 59.7 ± 6.8 1.60 ± 0.11 0.74 ± 0.10 1.19 ± 0.10 0.26 ± 0.04
D-IV 0.68 ± 0.08 2.8 ± 0.2 6.8 ± 1.1 0.38 ± 0.02 43.8 ± 2.7 1.22 ± 0.11 0.50 ± 0.05 0.61 ± 0.06 0.14 ± 0.01
* Value was calculated based on the values of the stationary growth phase (mean ± σcells). ** Value was calculated based on Xinoc and
Xmax. Xmax: maximum cell concentration on the planar growth surface. PDL: population doubling time. EF: expansion factor. µ: specific
cell growth rate. td: doubling time of cell population. YLac/Glc: lactate yield per glucose equivalent. qGlc: specific glucose consumption rate.
qLac: specific lactate pro-duction rate (growth-dependent). qAmn: specific ammonium production rate (growth-dependent).
3.4. Characterization of Human Expanded ASCs
3.4.1. Flow Cytometry Analysis of hASCs Grown in UrSuppe Medium
The growth rate is not the only parameter that is important in the cell culture process.
In fact, a crucial feature for a stem cell culture medium is its ability to “seal the undiffer-
entiated status” and prevent slow and spontaneous differentiation of the cells during the
in vitro culture and amplification phase. Thus, using flow cytometry during passage P0,
P1, and P2, we followed some surface markers’ expression, which may indicate whether
the hASCs display a stable phenotype or are drifting spontaneously away and starting
to differentiate into early adipocyte. Unfortunately, the canonical markers [27] used for
characterization of “mesenchymal stem cells” (CD73, CD90, CD105) are not sufficient to
clearly distinguish hASCs from other cells [61] and to evaluate their degree of stemness.
Therefore, we decided to include some recently described markers in our flow cytometry
panel [45,62,63], which are expressed by early precursors and can help to sketch lineage
hierarchy relationships between the cells. As shown in Figure 5A, the canonical markers
CD73, CD90, CD105, the new ones, as well as CD26, CD54, CD55, CD140a, and CD142, are
highly expressed. Most importantly, all these markers do not change very much during the
passaging of the cells. The CD34 marker, which typically characterizes freshly extracted
hASCs, tends to disappear during passaging [32,64]. Given that this marker, together
with CD146, is associated with adipogenic differentiation [30,33], its fast decrease during
passaging can be regarded positively and suggests that the in vitro conditions promote an
early precursors state of the cultured cells. hASCs can be considered negative for CD106,
and its expression does not increase during culture. This marker is used to discriminate
hASCs from BM-MSCs, which, on the other hand, are associated with CD106+ [27]. CD36
is a very useful surface antigen because it labels progenitor cells with a particular sus-
ceptibility to undergo terminal adipogenic differentiation. Its expression is correlated
with an increase in intracellular neutral lipid content [40,41]. Furthermore, it is also the
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ideal marker to determine if cells spontaneously start to differentiate during the culture
time because it is highly expressed in mature adipocytes [30,39]. As shown in Figure 5A,
this is not the case, and CD36 expression remains very low during the passaging of the
hASCs. Another marker with high and stable expression is CD95 (Fas Receptor, FasR) [65].
This observation suggests that the cells can be eliminated by activating the natural apop-
totic program. CD248 is involved in hypoxic regulation, angiogenesis, inflammation, and
reorganization of the extracellular matrix. It is expressed at low levels in stromal and
perivascular cells, but increased in the setting of tumor growth, inflammation, and injuries
associated with fibrosis. Lack of CD248 in mice confers protection against the growth
of some tumors and several inflammatory diseases [66]. Therefore, this is a marker that
labels pathophysiological or malfunctioning cells. As shown in Figure 5A, the number
of CD248 positive hASCs is very low and remains constant during the passaging of the
cells. The impact of the UrSuppe medium on hASCs’ morphology and phenotype can also
be monitored by following the shift in cell size and granularity during culturing of the
cells. Using flow cytometry, the size can be measured by means of forward scatter light,
and granularity by side scatter light. Normally, stem cells are small in size and have a
low degree of granularity. When they start to differentiate or go into senescence, these
two parameters increase [67,68]. Figure 5B displays the analysis of many measurements of
hASCs obtained from several donors. Interestingly, the size of the cells slightly increases
during the transition from P0 to P1, while the granularity decreases. On the other hand,
during the transition from P1 to P2, both parameters increase compared with P0 or P1.
Taken together, we conclude that our cell culture medium UrSuppe is able to support the
growth of hASCs right from the beginning in defined serum-free conditions by maintaining
a high expression of markers associated with an undifferentiated status and constantly
keeping some markers that indicate a low progressive differentiation of hASCs.
Figure 5. Flow cytometry analysis of cells at P0, P1, and P2 (A) Flow cytometry expression profile of selected markers. Data
represent an average of three different samples. During culture passaging, the profile of the cells remains similar except for
CD34. Data of positive cells are calculated on specific isotype controls. (B) Size distribution after isolation, during passages,
and after differentiation (FCS: forward scatter and SSC: side scatter). P0, P1, P2: Indication of the passage number of hASCs
grown in UrSuppe medium; ASCs found in the SVF as described and explained in Section 3.1; white adipose tissue (WAT)
and beige adipose tissue (BAT) represent white or beige induction, respectively. Each point’s coordinate is the mean of three
different samples; bars represent standard deviation.
3.4.2. Expression Levels of Some Marker Genes Measured by RT-qPCR
Similar to flow cytometry, we used RT-qPCR to monitor stemness or differentiation-
related genes. The cells used for this study were extracted from human subcutaneous
adipose tissue. Thus, we reasoned that the default differentiation pathway of these cells
should be towards adipogenesis in spontaneous unwanted and uncontrolled matura-
tion. In recent years, several essential genes have been discovered that are important for
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maintaining the stemness of hASCs, while others are essential for the differentiation and
maturation of these cells. A schematic representation of adipogenesis is shown in Figure 6A.
Therefore, some of these genes are very useful as markers in RT-qPCR assays to verify the
differentiation status of the in vitro expanded hASCs. Further information and references
about the marker genes used for this study can be found in Supplementary Information
(Tables S6–S8).
Figure 6. (A) Factors that positively or negatively regulate the adipocyte differentiation process. Different regulatory
proteins act at early and later stages to control adipogenesis. (B) Expression levels measured by RT-qPCR of genes involved
in cell stemness or cell differentiation: (B1) stemness maintenance genes; (B2) differentiation regulators/markers; and
(B3) lineage hierarchy markers. Primary hASCs from three different donors were analyzed at passages P0, P1, and P2. The
three upper bar graphs show the relative fold-expression change of the different markers at P2 compared with hASCs at P0
(n = 3, error bars represent S.E.M.). The three lower figures represent the same data as the heatmap for the three different
categories.
To facilitate analysis, the selected genes were subdivided into three groups:
(1) Stemness Maintenance Genes: PREF1, SOX9, ZFP521, WISP2, NOTCH1, DLL1;
(2) Differentiation Regulators/Markers: PPARG, ZFP423, RUNX2, CD146, WISP1, DKK1,
CD34, CD36, α-KLOTHO;
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(3) Lineage Hierarchy Markers: CD26, CD55, CD142, CD248.
Figure 6B shows the results of the RT-qPCR measurements. In the category “Stemness
Maintenance” (Figure 6B1), the expression profile of these genes at passage P2 was not
significantly different from that at P0. The level of PREF1 and WISP2 was nearly unchanged.
In contrast, the others showed only slight reductions, represented in the corresponding heat
map by only white color or different shades of blue. In the second category, “Differentiation
Regulators/Markers” (Figure 6B2), we notice an upregulation between P0 and P2 of the
gene PPARG, WISP1, and DKK1, which was compensated by a slight reduction of other
differentiation markers such as CD34, CD36, CD146, ZFP423, and α-KLOTHO. RUNX2 is
a transcription factor essential for osteoblast differentiation and chondrocyte maturation.
This marker is very useful for verifying whether hASCs begin to differentiate spontaneously
towards the osteo- or chondro-lineage. In the corresponding heatmap below, the white color
and the blue shades prevail over the red colors, so the marker/regulator gene expression’s
general trend does not indicate a dramatic change in their expression at P2. Finally, with
the third category, the “Lineage Hierarchy Markers” genes, which were recently described
by David Merrick et al. [45], their trend is more oriented towards the status quo or a
slight increase in the expression of the tested genes at P2 (Figure 6B3). This is graphically
highlighted in the heat map below the corresponding bar graph, where white and red
shades predominate. Thus, as seen before, with the flow cytometry analysis, we can
conclude that it is possible to grow and amplify hASCs up to passage P2 with our UrSuppe
culture medium without compromising the undifferentiated state of the cells.
3.5. hASCs’ Differentiation with Serum- and Xeno-Free Media
3.5.1. hASCs Induced in Defined Conditions to Differentiate into White or Beige
Adipocytes
Expansion of hASCs represents only the first step in a cell therapeutic protocol. In fact,
before using these cells, it is necessary to induce their maturation/differentiation into a
“stable” and specific lineage (e.g., adipocyte, chondrocytes, osteocytes, muscle cells, and so
on). This is very important to reduce or avoid the risk of differentiation into an unwanted
cell type or the potential risk of stimulating the growth of undetected tumors (bystander
tumor formation) [69]. To confirm that hASCs expanded in UrSuppe retain their ability of
multi-lineage differentiation, we perform a classical tri-lineage differentiation assay using
a commercially available kit. Adipogenic differentiation was determined by observing
the presence of Oil Red O-stained fat vacuoles in cells. The chondrogenic differentiation
was evaluated by Alcian Blue staining and, finally, the osteogenic differentiation capacity
was highlighted by Alizarin Red S staining. We found that hASCs expanded in UrSuppe
medium showed trilineage differentiation capabilities (see Supplementary Information
Figure S7 and paragraph S7: Differentiation assay to verify hASC multipotency).
There are numerous possible applications of adipose tissue in regenerative medicine [70–72],
and some of them were unexpected and surprising until recently [73]. This without forgetting
the interest in finally being able to study the biology of adipocytes in vitro under defined cell
culture conditions [19]. As a first step in this direction, we developed xeno- and serum-free
media, which induce the maturation of hASCs into white or beige adipocytes and which we
named “UrSuppe-white adipose tissue” (US-WAT) and “UrSuppe-beige/brown adipose tissue”
(US-BAT). To evaluate our media’s adipogenic differentiation potential, hASCs were initially
seeded and expanded in UrSuppe basal medium until confluency was reached. Adipogenic
differentiation was then induced with US-WAT medium for ten days or with US-BAT medium
for seven days. Human ASCs efficiently differentiated into pre-adipocyte accumulating lipids
as visualized by the Oil Red O staining for both media (Figure 7A–C). The dye was extracted
from the cells using 2-propanol, and absorbance was photometrically determined to enable
quantitative measurements. As shown in Figure 7D, intracellular lipid accumulations are tripled
when cells are cultured with either the US-WAT or US-BAT medium. As opposed to white
adipocytes, both brown and beige adipocytes possess thermogenic properties and thus can
produce high levels of heat via uncoupled respiration. This is achieved by expressing high
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levels of uncoupling protein 1 (UCP1) to dissipate energy in the form of heat by uncoupling the
mitochondrial respiration. This phenomenon, the mitochondrial membrane’s depolarization,
can be visualized by the JC-10 molecule [74]. This dye accumulates in mitochondria of healthy
cells with polarized mitochondrial membranes, generating an orange emission profile. As the
membrane potential decreases, which results in the failure to retain JC-10-aggregates in the
mitochondria, JC-10 monomers are generated, resulting in a shift to green emission. As shown
in Figure 8, this happens when hASCs are cultured with the induction medium US-BAT.
Figure 7. Adipose conversion shown by lipid staining with Oil Red O. Human ASCs at early passage (P3) expanded
in Ursuppe basal medium are easily induced to differentiate into early adipocytes. Two different xeno- and serum-free
induction media developed in our laboratory were used for these assays. Fold magnification 100×. Scale bar 100 µm.
(A) Not induced hASC, grown on UrSuppe basal medium (negative control); (B) hASCs after ten days of white adipogenic
induction with UrSuppe-white adipose tissue (US-WAT) medium; (C) hASCs after seven days of beige adipogenic induction
with UrSuppe-beige/brown adipose tissue (US-BAT) medium. (D) Evaluation of the adipogenic differentiation based on
the quantification of the Oil Red O absorbance, normalized for the number of cells present in the cell culture vessel. Data
represent the mean absorbance ± SEM. To detect significant differences, a one-way analysis of variance (ANOVA) test was
performed. * p-value < 0.05.
3.5.2. RT-qPCR Analysis of Induced hASCs
To confirm the cells’ correct differentiation, RT-qPCR analysis was performed for se-
lected genes involved in the adipogenic process. Most of them are involved in the formation
of lipid droplets and the adipocyte’s metabolic regulation, a process that occurs in white or
in beige/brown adipose tissue. Further information about these genes, including a short
description and references, can be found in Supplementary Information (Tables S6–S8). As
shown in Figure 9, all marker genes linked to adipose-development and maturation are
strongly upregulated when hASCs are cultured in both WAT and BAT induction media,
without a significant difference between the two inductions. The only gene that was down-
regulated is PREF1. This was expected as this marker plays a crucial role in preserving an
undifferentiated status and blocking adipogenic differentiation [75,76]. However, when the
cells begin to mature into adipocytes, PREF1 is drastically downregulated. Interestingly,
we noticed that the LEPTIN expression levels were statistically significantly higher in the
WAT induction than in the BAT induction. This is in line with what is known about this
hormone, mainly produced by the WAT and poorly expressed in BAT [77,78]. Finally,
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Figure 9B shows the expression levels of two of the central genes responsible for the for-
mation of brown/beige adipose tissue, UCP1 [79] and PGC1α [80,81]. Both are detected in
hASCs induced with US-WAT or US-BAT media. However, as expected, their expression is
significantly higher when the BAT induction medium is used.
Figure 8. JC-10 staining shows mitochondrial depolarization after culturing confluent hASCs in the US-BAT medium.
(A1–A3) Negative control: not induced hASC, grown on UrSuppe basal medium. (B1–B3) BAT induction, green fluorescence:
changes of the membrane potential (caused by UCP1 expression). (1) Representative microphotograph taken with a 590 nm
filter showing JC-10 aggregates in normal cells. (2) Representative microphotograph taken with a 525 nm filter showing
JC-10 monomer in depolarized mitochondria. (3) Merged. Fold magnification 100×. Scale bar 150 µm.
3.5.3. Flow Cytometry Analysis of Induced hASCs
In a similar way to what was shown before in paragraph 3.1 with the SVF, we chose
12 reliable cell surface proteins that characterize undifferentiated ASCs or early adipocytes.
These markers can be classified as follows:
• Canonical ASCs markers: CD73, CD90, CD105 [27];
• Adipose progenitor cell markers: CD26 (DPP4), CD54 (ICAM-1), CD55 (DAF), CD142
(tissue factor, TF), CD248, Endosialin [45,62,63];
• Adipogenic differentiation markers: CD34, CD36, CD146 [30,33,34,41];
• Beige adipocyte marker: CD137/TNFRSF9 [82–84].
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Figure 9. RT-qPCR analysis of different genes involved in WAT and BAT differentiation. (A) Expression of seven common
genes involved in adipogenesis regulation. (B) Expression of the two main common genes involved in the maturation of
brown/beige adipose tissue. Data represent the mean fold-increase expression in different medium ± SD versus ASC. Gene
expression is normalized to undifferentiated ASC (indicated on the “Expression” y-axis), the different expression of genes
in WAT or BAT differentiation medium are indicated on the “Fold Increase” y-axis on the logarithmic scale. To detect a
significant difference, a one-way ANOVA was performed for each gene. * p-value < 0.05; ** p-value < 0.01 *** p-value < 0.001.
Human ASCs harvested from three different donors were either maintained in culture
as undifferentiated cells with UrSuppe basal medium or differentiated with US-WAT or US-
BAT. Before harvesting the cells, the undifferentiated hASCs showed the typical elongated
spindle-shaped morphology. In contrast, most induced cells were polygonal with numerous
cytoplasmic lipid droplets of different sizes, as shown in Figure 7A–C. To control for
changes in surface marker expression due to the different culture media, the cells at passage
two were detached from the 60 mm coated Petri dishes, as described in Section 2.1.3., and
were analyzed by flow cytometry. As shown in Figure 10, the majority of the hASCs grown
in UrSuppe basal medium were positive for the “canonical markers” (CD75, CD90, CD105)
and for the majority of the recently described “adipose progenitor cell markers” (CD26,
CD54, CD55). We noticed that the percentage of CD105 positive hASCs was lower than the
two other “canonical markers”. However, this phenomenon was already reported in other
studies, where cells were grown in serum-free conditions [85,86]. Two surface proteins of
the group “adipogenic differentiation markers”, CD142 and CD248, were only detected on
a small percentage of the hASCs. CD142 was described by Schwalie et al. [62] as a marker
of a small subpopulation of early precursors, which can suppress adipocyte formation
in a paracrine manner. Thus, the fact that CD142 is expressed by progenitor cells with a
regulatory task makes it reasonable only to expect its presence on the surface of a small
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percentage of hASCs. CD248 was identified by Merrick et al. [45] after single-cell RNA
sequencing and cell trajectory analyses and classified as one of few markers to be expressed
by very early adipose progenitor cells. However, new results have shown that CD248
expression could mark malfunctioning cells [66]. Given this information, it is very positive
that only a small percentage of the hASCs grown in UrSuppe basal medium are CD248
positive. Likewise, positive percentages for CD34, CD36, and CD146 remain low when
culturing hASCs with the UrSuppe medium. In contrast, the percentages of positive cells for
the “adipogenic differentiation markers” clearly increased when hASCs were differentiated
with US-WAT or US-BAT medium. In parallel, some markers of the undifferentiated status,
such as CD54, CD55, and CD105, show a strong decrease in positive cells. Finally, the
number of CD137 positive cells clearly increased only when the hASCs were induced with
US-BAT medium. Taken together, these data suggest that it is possible to grow hASCs
under xeno- and serum free conditions while preserving their undifferentiated status.
This analysis also revealed that the differentiation media were effective by boosting the
expression of the three “adipogenic differentiation markers” and of CD137 with US-BAT.
Figure 10. Percentages of cells found to be positive for the 13 surface markers chosen for this analysis. Bar chart of
summarized flow cytometry data for hASCs cultured in UrSuppe basal medium (white bar) or for cells differentiated in
either US-WAT (grey bar) or US-BAT (black bar) medium. The chart shows the mean percentage of positive cells for the
indicated surface markers. Average of data obtained from three different donors (n = 3, error bars represent S.E.M.).
3.5.4. Comparative Secretome Profile Analysis of Undifferentiated and Differentiated
hASCs
Because some polypeptides are only produced and secreted during certain precise
stages of development or maturation, they can be used to diagnose a specific metabolic
state or a specific differentiation degree of the cells under investigation. To assess 58 hu-
man adipokines’ presence, we used a commercially available “Proteome Profiler Human
Adipokine Array” (Figure 11, and Supplementary Material Figure S8 and Tables S9 and
S10). Interpreting and finding a biological sense for a proteome profiler array is always
very difficult, especially if many polypeptides are detected. In this case, we notice some
trends that facilitate interpreting the obtained results.
First, the detected polypeptides were already associated by other reports to the adipose
tissue’s secretome (for review, see [87]). Second, to facilitate the data’s comprehension, it
was possible to group the secreted polypeptides according to some characteristic traits that
unite them. The three profiles are different, as can be seen by looking at Figure 11 and
Table S9.
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Figure 11. Proteome profiler of hASCs grown in UrSuppe medium (blue bar), US-WAT (red bar), or US-BAT (green bar)
induction medium. Data are represented as mean pixel intensity (MPI) of fluorescence measured by the Licor acquisition
system. Measured values were normalized on background fluorescence and on positive control to obtain a relative MPI.
This experiment was performed with hASCs obtained from the biopsy of one donor. The following factors are not shown in
the graph because of a very low expression in undifferentiated hASCS: Chemerin, Fibrinogen, IGFBP-2, LIF, PAPP-A, PCSK9,
Aerpin A8.
As a first very positive result, we found that two signature adipokines (adiponectin
and leptin, reviewed in [88]) for differentiated cells were very low or missing in the
supernatant of non-induced hASCs, while present in cells cultured with the WAT or BAT
differentiation medium. Interestingly, it is known that leptin is secreted mostly by mature
subcutaneous white adipocytes [89], and indeed, this is what we observed in this assay
and by the RT-qPCR measurements shown in Figure 9.
Next, we noticed the presence of three Cathepsin family members. These proteins
are proteases that play different crucial roles in mammalian cellular turnover. Cathepsin
D [90] (aspartyl protease) and Cathepsin L [91] (cysteine protease), as well as Cathepsin
S (cysteine protease), play essential physiological roles in the adipose tissue and are
essential for remodeling the extracellular matrix (ECM) [92]. Interestingly, Cathepsin D
also has mitogenic activity independent of its proteolytic activity, and its knock-out in mice
revealed that it is indispensable for postnatal tissue homeostasis [93]. Together with the
proteases, we detected three protease inhibitors (Fetuin-B, PAI-I, Timp-1). Among these
three proteins, the most exciting factor is Timp-1 (tissue inhibitor of metalloproteases).
This inhibitor orchestrates with the matrix metalloproteases (MMP) the regulated turnover
of the ECM, and its role is to control the proteases’ enzymatic activity [94]. Surprisingly,
it was also discovered later that TIMPs act as signaling molecules with cytokine-like
activities, thus influencing various biological processes, including cell growth, apoptosis,
differentiation, angiogenesis, and oncogenesis. All these functions are independent of
MMP inhibition [95,96].
The proteome profiler array also highlighted several cytokines [97] and chemokines [98]
in the cell-conditioned culture media: IL-6, IL-8, CCL2/MCP-1, CCL5/Rantes, M-CSF, MIF,
complement factor D, Pentraxin-3/TSG-14, and Lipocalin-2. It is challenging to find a
common denominator for these secreted factors, mostly associated with an inflammatory
condition. However, it has been reported recently that proinflammatory signaling in the
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adipocyte is required for proper adipose tissue remodeling and expansion [99,100]. Human
ASCs in culture are likely to secrete these cytokines and chemokines to form the best envi-
ronment around them to grow and proliferate. It is well known that, in the adipose tissue,
numerous adipocyte-derived adipokines involved in modulating metabolic homeostasis
also display immunomodulatory properties. For example, we can mention the pleiotropic
cytokine IL-6, which was attributed to an important role in the “browning” of the white
adipose tissue [101]. The last factor in this group is Lipocalin-2, which has been attributed
to the innate immunity to sequester iron and prevent its use by bacteria, thus limiting
their growth. However, Lipocalin-2 may preserve adipose tissue function and protects
against age-related metabolic misfunctions. Interestingly, this factor was found only in the
supernatant of non-induced hASCs [102].
The next group of related polypeptides consists of the insulin-like growth factor-
binding proteins (IGFBPs). One of their primary functions is to regulate the action of
insulin-like growth factors (IGF-I, IGF-II) by controlling the accessibility of these peptide
hormones to their receptors [103]. Both IGF-I [104] and IGF-II [105,106] are pro-adipogenic.
It has been shown that IGFBP-4 binds IGF-I and its expression negatively correlates with
adipose tissue growth [107]. IGFBP-6 can bind IGF-II, and IGFBP-7 can bind both IGF-I and
II [108]. Thus, it is likely that these three members of the IGFBP family are anti-adipogenic.
In fact, the general tendency is to decrease when the cells are induced to differentiate.
The most intriguing member of this group of secreted factors is IGFBP-7, also known as
Angiomodulin (AGM), and reported to be expressed by the developing vasculature [109]. It
binds chemokines and growth factors, including VEGF-A [110,111]. Therefore, IGFBP-7 is
now considered proangiogenic in the developing vasculature, that is, in concert with VEGF-
A and potentially other angiogenic factors, it guides and stabilizes the nascent vasculature.
Interestingly, IGFBP-7 and VEGF (reviewed in [112]) are simultaneously found only in the
supernatant of uninduced hASCs. Two other polypeptides related to angiogenesis and
cell proliferation were detected: hepatocyte growth factor (HGF, reviewed in [113]) and
angiopoietin-like factor [114].
We detected the soluble version of CD26, CD54, and Pref-1 as hASC-specific secretions.
These proteins are encoded by genes classified as adipose progenitor cell markers. There-
fore, we consider their exclusive presence in the conditioned medium of undifferentiated
cells as a positive result that confirms the data obtained previously by flow cytometry or
RT-qPCR.
Finally, Nidogen/Entactin is a typical component of the ECM found in the adipose
tissue [94] and, therefore, it is not surprising to find it in the cell supernatants.
In conclusion, the secretion profile of hASCs is different from that obtained with
cells induced to differentiate into white or beige adipocytes. Some typical adipokines that
signal ongoing adipogenesis, such as Adiponectin and Leptin, are very low or completely
missing. Conversely, some factors known to be anti-adipogenic, or angiogenic, or related to
progenitor cells are mainly present in the supernatant of non-induced hASCs. Thus, we can
cultivate hASCs with the UrSuppe medium while maintaining their undifferentiated status.
3.6. Is Human Platelet Lysate the Best Possible Substitute for FBS?
In these last years, the use of FBS and other animal derivatives for ex vivo expansion
of human cells has been discouraged by regulatory authorities to reduce the risk of trans-
mitting prions and other zoonoses and avoiding xenogeneic immune reactions in the host.
Consequently, the authorities demand important scientific justifications if one wants to
use FBS for the cell culture process, as well as numerous specific analyses demonstrating
the absence of potentially dangerous contaminants, such as viruses, prions, and endotox-
ins [115]. Faced with these difficulties, it is not surprising that researchers have developed
human alternatives to FBS for cell expansion. Human platelet lysate (hPL) is currently
considered the ideal substitute for FBS and is regarded as an acceptable alternative by the
regulatory authorities [116]. However, the use of hPL presents some disadvantages [117].
Indeed, similarly to FBS, it is not precisely defined, and this implies that hPL may contain
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growth factors or hormones that can induce spontaneous differentiation of the cultured
progenitor cells. Several years ago, it was demonstrated that sera of different species,
including human, contain an “adipogenic factor”, which induces adipose conversion in un-
differentiated cells. Using the same strategy applied by Walid Kuri-Harcuch and Howard
Green [118], we wanted to determine whether hPL also contains pro-adipogenic activities.
For this purpose, hASCs at passage 2 were cultured in 60 mm Petri dishes in UrSuppe
basal medium until confluency. At this point, the cell culture medium was changed to one
based on the adipogenic induction medium US-WAT supplemented with 0.5%, 1%, or 3%
hPL. The control test received US-WAT medium without hPL supplement. As shown in
Figure 12A, supplementing US-WAT with hPL strongly boosted the conversion of hASCs
into adipocytes, as evidenced by the increasing number of fat vesicles stained with Oil
Red O. This dye was then extracted from the stained samples with 2-propanol, and the
optical density (OD) was read with a photometer. Figure 12B confirms increased lipid
storage in those samples where US-WAT was supplemented with 0.5%, 1%, or 3% hPL.
This rise in measured triglycerides is not due to increased cell numbers because the data
were normalized on every dish’s number of nuclei. We concluded that hPL, similarly to all
the other undefined sera used in cell culture, contains large amounts of pro-adipogenic
factors. This is not a surprise, as proteomics studies completed in recent years on the
composition of hPL have revealed the presence of numerous factors, e.g., IGF-1 and several
members of the bone morphogenetic proteins (BMPs) family [119,120]. These proteins play
essential roles in the induction of adipogenesis and/or chondrogenesis, respectively. Taken
together, we conclude that hPL may not be the best choice to replace FBS in cell culture
because it does not rule out a spontaneous, undesired slow differentiation of the cultured
undifferentiated cells.
Figure 12. Oil Red O staining and quantification to evaluate the effect of hPL on adipogenic differentiation. hASCs after
10 days of adipogenic induction with or without hPL supplement (0.5%, 1%, 3%). (A) Representative phase-contrast
microphotographs illustrating triglycerides accumulation: (A1) US-WAT only, (A2) US-WAT + 0.5% hPL, (A3) US-WAT +
1% hPL, and (A4) US-WAT + 3% hPL. Fold magnification 100×. Scale bar 100 µm. (B) Quantification of Oil Red O staining.
100% 2-propanol was used as background control and subtracted to the four test samples’ measured optical densities (ODs),
which were then normalized on the number of nuclei present on every dish. The data refer to the value obtained with cells
grown with US-WAT only, thus this bar chart shows the fold variation of absorbance related to this sample. The results
represent the average ± SD of three different samples. Statistical analyses were performed as one-way ANOVA using
Prism7 software, ** p < 0.01.
4. Discussion
Adipose tissue is remarkably understudied compared with other organs. Until the
mid-20th century, it was simply considered as a metabolically inert connective tissue with
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no particular functional properties, except the ability to store excess energy in the form
of intracellular triglycerides. However, in recent years, owing to increasing obesity and
obesity-associated pathologies globally, this tissue has gained significant attention from
the research community. Now, it is recognized as a proper active endocrine organ at the
center of energy balance and nutritional homeostasis, mediating the regulation of multiple
organs and tissues [1,2,121]. Finally, many groups have shown independently that the
adipose tissue is particularly rich in adult stem cells, which can differentiate, along multiple
pathways, raising great hope in regenerative medicine [72,122]. A striking aspect of adipose
tissue is the extreme complexity of its developmental biology. Recent studies suggest that
anatomically distinct white adipose tissue depots originate from different precursors
that are destined to become subcutaneous or visceral adipocytes [3,21,123]. Furthermore,
adipose depots’ initial development during the fetal and early postnatal period depends
on precursors distinct from those that contribute to tissue maintenance and remodeling in
adulthood [124,125]. All of this probably leads to the intra-depot heterogeneity recently
documented in the adipose tissue [20,126]. This extraordinary complexity is also reflected
in the fact that the precise anatomical location in the adipose tissue of these progenitor
cells is still unclear. Many reports indicate a perivascular localization of progenitor cells,
suggesting a mural cell origin of adipogenesis. However, other recent studies revealed
non-perivascular adipose precursor populations [45,127]. Thus, it is not surprising that
this diversity has led to the characterization of various cell types believed to be WAT
progenitors (reviewed in [128]).
Initially, Rodeheffer et al. identified and Berry et al. characterized a subpopulation
of early adipocyte progenitors defined as CD24+ CD29+ CD34+ Sca-1 (Ly6A)+ in mouse
WAT [31,129]. Since then, many studies have found distinct adipocyte progenitor cells
with various cell surface proteins expressed in WAT [128] and, recently, single-cell RNA
sequencing (scRNAseq) technology was used to find new gene markers able to better
define the cellular subpopulation involved in adipogenesis (reviewed in [130,131]). This
new way to search for new markers led David Merrick et al. [45] to identify distinct types
of progenitor cells in murine subcutaneous adipose tissue, which were subdivided into
three hierarchical groups based on their gene expression patterns (reviewed in [132,133]).
The first population, termed “interstitial progenitor cells” (IPCs), is highly proliferative
and undifferentiated. These cells are CD24− CD26+ CD34+ CD54− CD55+ CD142− and are
localized in the “reticular interstitium”, a recently described anatomically distinct structure
that encases many organs [134]. IPCs then give rise to the two other subpopulations, which
are intercalated between mature adipocytes. So, in the mouse, group two cells are defined
as CD24− CD26− CD34+ CD54+ CD55− CD142−, whereas group three cells are defined as
CD24− CD26− CD34+ CD54+ CD55− CD142+. Similarly, Merrick et al. found for human
subcutaneous adipose tissue a gene expression profile for group 1 and 2 similar to that of
mouse, while group three could not be assigned because, in humans, CD142 is abundantly
expressed both in group 1 and 2. So, the human IPCs cells (group one) are defined as
CD24− CD26+ CD34+ CD54+ CD55+ CD142+ CD248+, whereas group two cells are defined
as CD24− CD26− CD34+ CD54+ CD55− CD142+ CD248−.
The results obtained thanks to scRNAseq technology and published recently by a few
research groups [45,62,63], reviewed in [130], are very important and cannot be ignored.
Therefore, we selected five of these new markers (i.e., CD26, CD54, CD55, CD142, and
CD248), along with five canonicals (CD34, CD73, CD90, CD105, and CD146), to investigate
the cells grown in UrSuppe medium. As shown in Figure 10, nearly 100% of the cells are
positive for CD26, CD54, CD73, CD90, and CD105, while about 50% of them are positive for
CD55. Simultaneously, only small percentages are positive for the differentiation markers
CD34, CD36, and CD146. This seems to correspond to a markers profile compatible
with undifferentiated cells, which may be described as CD24− CD26+ CD34− CD54+
CD55+/− CD142− CD248− (as well as CD73+, CD90+, CD105+). Therefore, concerning
the classification suggested by Merrick et al. [45], these cells could be classified as an
intermediate form between groups one and two. Their differentiation with the induction
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media US-WAT or US-BAT gave interesting results. As expected, adipogenic markers
increased, while only CD54 and partially CD55 (only with US-WAT) and CD105 decreased
significantly among the progenitor cell markers. We were surprised that CD26 remained
well expressed even when the cells were cultured with the induction media. Flow cytometry
is notoriously difficult to apply to investigate pre- or mature adipocyte cell surface markers
expression [108] because the cells are very large, fragile, and have high buoyancy. Thus,
many of them are damaged or lost during the samples’ preparation, and less differentiated
cells have a better chance of being analyzed. We also remarked that CD26 is present on
many types of cells of the SVF and found in combination with CD36, which is a marker
associated with adipogenesis [40,41] (Figure 1B). This suggests that this surface protein
is not strictly linked with progenitors, but can also be expressed by committed or more
mature cells. This could reduce its usefulness as a tool for selecting cells with a high degree
of “stemness”.
Another exciting marker used in our study is CD142. This surface protein was associ-
ated with progenitor cells named Areg, capable of negatively regulating adipogenesis [62].
However, we found during our study that Dexamethasone strongly induces CD142, a
synthetic corticosteroid typically used in induction media for its strong pro-adipogenic
effects [135,136] (Figure 10 and Supplementary Materials Figure S9). Thus, it is difficult
to reconcile this observation with the claim that CD142 labels cells with anti-adipogenic
potentials when an adipogenesis-promoting hormone induces its expression. This per-
plexity is also shared by Merrick et al., who found CD142+ cells to be highly adipogenic
both in vitro and upon transplantation in vivo [45]. In 2008, the first study describing a
population of progenitor cells postulated the existence of inhibitory cells in the WAT [31].
Petra Schwalie et al. have again drawn attention to this aspect, but further studies will be
needed to complete Areg’s characterization and to understand the role of CD142 in this
context [62].
Recently, again thanks to the scRNAseq technology, Ogury et al. reported the char-
acterization of the CD81 surface protein as a marker of beige adipocyte precursor cells,
which give rise to thermogenic adipocytes in subcutaneous adipose tissue [137]. We tested
this marker in the context of the flow cytometry platform we usually use to characterize
the cells of the SVF. As shown in Supplementary Materials Figure S10A, CD81 is not a
rare antigen and is present in the three main subgroups with which we divide the cells
of the SVF (i.e., CD34+CD146−, CD34-CD146+, and CD34+CD146+). Many of these cells
are also double positive for CD36, a notorious marker signaling adipogenic differentiation.
We have consistently observed that the CD34+CD36+ subpopulation cells display the
highest CD81 mean fluorescence compared with the other two subgroups (Supplementary
Materials Figure S10B). Finally, this marker is abundantly expressed by almost the totality
of the hASCs grown and expanded with the UrSuppe cell culture medium (Supplementary
Materials Figure S10C). CD81 belongs to the Tetraspanins, a large family of transmembrane
proteins ubiquitously expressed and implicated in cell proliferation, differentiation, and
tumor invasion [138,139]. Thus, this marker is not exclusively expressed on beige adipocyte
precursors, but also by highly proliferative ASCs [137]. Taken together with these proper-
ties, it will be difficult for the CD81 marker to find practical applications by itself, such as
characterizing and/or purifying beige adipose progenitors from human adipose tissue.
The transmembrane phosphoglycoprotein CD34 was first identified as a hematopoietic
stem cell marker, but was later found on several nonhematopoietic cell types [140]. In
the clinic, this marker is associated with the selection and enrichment of stem cells for
bone marrow transplants. Therefore, because of these historical and clinical associations,
CD34 has always been linked with “stemness” in various systems, including hASCs.
Freshly extracted hASCs are CD34+ (Figure 1B), but they lose this marker upon plastic
adhesion and culture (Figures 5 and 10). This change in hASCs’ phenotype has been
considered as a differentiation process in response to the in vitro environmental changes.
However, various published studies and our direct observations suggested a different
interpretation to explain this phenomenon. Indeed, CD34 is expressed on the surface of
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mature adipocytes [30] and is upregulated when hASCs are induced to mature toward an
adipogenic lineage using a differentiation cell culture medium (Figure 10) [33]. These data
might suggest that CD34, at least in the adipose tissue, does not signal “stemness”, but
rather a marker of adipogenic differentiation expressed by early and mature adipocytes.
Therefore, the decrease in CD34 during the early stages of in vitro culture might signify
that the cells dedifferentiate and thus increase their “stemness”. This hypothesis might be
plausible given that the culture conditions are known to change the fate and potency of the
growing cells [141]. Furthermore, adipocytes have been shown to possess a high degree of
plasticity and can switch from a mature form to a less differentiated one [142]. All these
considerations are depicted in Figure 13. Finally, these thoughts led us to suspect that the
hASCs grown in UrSuppe medium may perhaps be placed in a hierarchical line upstream
to the IPCs described by Merrick et al. Single-cell RNA sequencing technology applied
to hASCs cultured according to our conditions may help us to understand whether this
hypothesis is correct or wrong.
Figure 13. Preadipocytes’ dedifferentiation induced by the ex vivo cell culture conditions.
Expanding undifferentiated cells in vitro without affecting their “stemness” is very
important. To achieve this, we developed a newly defined xeno- and serum-free medium,
called UrSuppe, specially formulated to grow hASCs. Studies focusing on hASCs grown
in serum-free media are relatively rare, and in Supplementary Materials Table S11, we
listed a good portion of them with some basic information and references. Using the
UrSuppe cell culture medium, we achieved specific growth rates for hASCs isolated from
different patients (i.e., age, health condition) comparable to those reported by other re-
searchers [58,59,143]. The maximum achieved cell densities were in a clinically significant
range, especially if the expansion processes are transferred to larger cultivation systems
(e.g., stirred single-use bioreactors in combination with microcarriers) in the future. FBS is
still the most used cell culture medium supplement, although it is an undefined cocktail
of numerous growth factors and hormones [144,145]. However, it is very difficult to seal
the “stemness” of the expanded hASCs with this component. Indeed, it was shown a
long time ago that FBS and other sera, including human, contain adipogenesis promoting
factors [118]. The same applies to the platelet lysate (PL); despite being produced from
human blood, it is a cocktail of numerous growth factors and hormones, some of which
have well-known adipogenic promoting activity [116,120] (Figure 12), which acts in an
unpredictable and uncontrolled way on the fate of the hASCs [146,147].
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For these reasons, this study’s main objective was to develop a chemically defined
cell culture medium containing specific components capable of supporting the growth of
hASCs while preserving their undifferentiated status. The UrSuppe medium is specific
for the cultivation of hASC and contains only recombinant growth factors and synthetic
hormones, which enhance the stemness, and is devoid of all known components that could
induce cell differentiation. To be consistent with the approach used to expand hASCs, we
also developed xeno- and serum-free (XFS) media to induce the maturation into white or
beige adipocytes. The fascination with adipose tissue has increased enormously because of
the worldwide escalation of obesity and related metabolic diseases. Therefore, it will also
be necessary to have cell models obtained under defined conditions to study in vitro the
adipocyte biology in health and disease.
The analytical results obtained during this study from hASCs cultured in UrSuppe
medium confirmed that the cells preserved an undifferentiated status and specific stem
characteristics. Typically, a well performing defined XSF medium, like UrSuppe, is unique
for the type of cell for which it was explicitly developed. For this reason, it is hardly suitable
for culturing other cell types [148,149]. This specificity linked to the type of cell of interest
can be considered an intrinsic disadvantage of defined XSF media. Changing the cell type
often forces the researcher to develop a new type of XSF medium. This task is not always
easy and can take time. However, we think that the advantages of developing this crucial
ancillary material for the cell culture are as follows:
- It is possible to improve/adapt the formula continuously.
- It facilitates subsequent steps (e.g., differentiation into mature lineages with specific
XSF induction media).
- It provides better access to troubleshooting.
- It provides better control over the cell culture conditions and thus over the whole
process.
Aside from the considerations, there are the classic motivations for excluding hPL
(reviewed in [117]) and FBS (reviewed in [148,150]) from the cell culture medium used
to grow therapeutic hASCs; indeed, when FBS is used, the risk of transferring infectious
agents from animals cannot be eliminated. Besides, FBS is engulfed by the stem cells
and may induce immune xenogenic rejection upon autologous transplantation into the
human patient [151]. Furthermore, except for blood and endothelial cells, all the other
tissue cells usually never come into contact with serum. They are in contact with the
interstitial fluid, which has a lower concentration of proteins than serum, and is specific
for each tissue or organ owing to a unique composition of secreted polypeptides and
metabolic molecules [152,153], which is thus a situation we can try to reproduce and
mimic in serum-free conditions. Finally, there are also serious ethical concerns about FBS’s
use concerning its harvesting and production process [154], not to mention the risk of
adulterated composition and unstable prices. All these are good reasons to move away
from undefined components in general and FBS in particular.
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Latin Symbols
Cmet (mmol/L) Substrate or metabolite concentration
e (-) Euler’s number (2.71828 . . . )
EF (-) Expansion factor
∆Glc (mmol) Difference in glucose concentration (glucose interval)
∆Lac (mmol) Difference in lactate concentration (lactate interval)
P (-) Passage number
PDL (-) Population doubling level
qmet (pmol/cell/d) Specific substrate consumption or metabolite production rate
t (d) Time
td (d) Doubling time
∆t (d) Time interval
XA(0) (cells/cm2) Cell concentration on planar growth surface at time point 0
XA(t) (cells/cm2) Cell concentration on planar growth surface at time point t
XA(tmax) (cells/cm2) Cell concentration on planar growth surface at the end of the cultivation
YLac/Glc (mmol/mmol) Lactate yield per glucose equivalent
Greek Symbols
µ (d−1) Specific growth rate
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